May, 2008 - LumeRx reported several events concerning its plans moving forward. Trial results analysis from work recently completed in India reveals current visible light approaches are not adequate as a primary treatment for H. Pylori. As a result of these findings, the Company's investors have decided to not invest further in LumeRx and to scale back operations. Jon McGrath has stepped down from his position as CEO with day-to-day responsibilities assumed by David Hendren of Catalyst Health Ventures. Catalyst and other investors are now considering the future course for the LumeRx. http://www.masshightech.com/stories/2008/05/26/weekly13-Future-is-unclear-as-LumeRx-shuffles-execs,-Gabrieli-ends-funding.html
No comments:
Post a Comment